Individualised compared with conventional dosing of enoxapari

Phase 1

Active, not recruiting

• Conditions: Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism; Atrial fibrillation; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12606000147583
• Lead Sponsor: QHDAC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-04-27
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Any patient (male or female) initiated or about to be initiated on treatment doses of enoxaparin.

Exclusion Criteria

Pregnancy, anticoagulation in the past 7 days, abnormal liver function test (more than twice the usual range).

Study & Design

• Study Type: Interventional
• Study Design: Not specified